What’s in Ozzi BIOMEnd® Butyrate: ingredients, amount and research
The best butyrate supplement we know how to make. One active, 1,000 mg of BIOMEnd® L-lysine butyrate per serving, with no sodium carrier and no added oils.
Last reviewed November 10, 2026
The formula, per 4 capsules
| Ingredient | Amount per serving |
|---|---|
| L-lysine butyrate (as BIOMEnd®) | 1,000 mg |
Each serving contains 1,000 mg of BIOMEnd® L-lysine butyrate. This is the complete ingredient, including L-lysine.
112 capsules, 28 daily servings per bottle. No sodium carrier and no added MCT, seed or other oils.
Butyrate
1,000 mg BIOMEnd® L-lysine butyrate per serving
Butyrate is a short-chain fatty acid made when gut bacteria ferment fiber. The cells lining your colon use it for energy.
That lining is an important part of your gut barrier. Butyrate is involved in keeping it functioning, which is why it matters for gut health. Ozzi supplies butyrate directly as BIOMEnd® L-lysine butyrate, giving you a daily way to support intestinal health.†
What the research shows
Gut-lining fuel. Roediger’s research showed that isolated human colon cells use butyrate for energy. When it was their only fuel, it accounted for about three quarters of their oxygen use.
Gut barrier. In a lab model of the gut lining, Peng and colleagues found that butyrate helped intestinal cells assemble tight junctions, the connections that help maintain the barrier.
Immune signaling. In mouse and cell studies, Furusawa and colleagues found that butyrate supported regulatory T-cell development, a mechanism involved in keeping gut immune responses in balance.
Digestive symptoms. In a randomized study of 66 people with IBS, microencapsulated sodium butyrate added to existing treatment reduced how often certain symptoms occurred.
Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man.
Colon-lining cells isolated from 14 human surgical specimens; oxygen use measured with butyrate, glucose and glutamine as fuels.
Butyrate supplied 73 to 75 percent of the cells’ oxygen use when it was the only fuel. The author concluded that butyrate made by gut bacteria is a major energy source for the colon lining, especially the lower colon.
Read the original publicationButyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers.
Caco-2 intestinal cell monolayers; butyrate exposure and AMPK-inhibition experiments.
Butyrate increased barrier resistance and promoted tight-junction assembly through an AMPK-linked process. Blocking AMPK prevented key barrier effects.
Read the original publicationCommensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells.
Mouse experiments and cultured T cells exposed to short-chain fatty acids.
Among the short-chain fatty acids tested, butyrate drove the development of regulatory T cells in the colon. These cells help keep gut immune responses in balance.
Read the original publicationMicroencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome.
66 adults with IBS on standard treatment; randomized, placebo-controlled; microencapsulated sodium butyrate added for 12 weeks.
The butyrate group had less pain during bowel movements at 4 weeks, and better urgency and bowel habits at 12 weeks. Changes in overall abdominal pain and gas were not statistically significant.
Read the original publicationWhy L-lysine butyrate
We chose BIOMEnd for its L-lysine form and published human absorption research. It pairs butyrate with an amino acid instead of sodium.
No sodium carrier. BIOMEnd pairs butyrate with L-lysine instead of sodium. The ingredient has no sodium in its chemical structure.
No added oils. Ozzi’s capsule formula contains no added MCT, seed or other oils. Some tributyrin softgels include added oils.
A milder odor. BIOMEnd’s supplier describes a milder odor than traditional butyrate ingredients. A slight odor may still be present.
The human absorption study
Compared with the tested tributyrin product, BIOMEnd produced about five times the mean peak blood butyrate in a 2025 study. Ten healthy men tried each form, with equal amounts of butyric acid.
Mean blood exposure over 3.5 hours was 75% greater with BIOMEnd than with the tested tributyrin product, and its mean observed peak came at 20 minutes, compared with 51.5 minutes for tributyrin.
| Human study | BIOMEnd® L-lysine butyrate | Sodium butyrate | Tributyrin |
|---|---|---|---|
| Mean peak blood butyrate | 4.53 µg/mL | 2.51 µg/mL | 0.91 µg/mL |
| Mean time to observed peak | 20 minutes | 22.5 minutes | 51.5 minutes |
| Mean blood exposure over 3.5 hours | 189 µg·min/mL | 144 µg·min/mL | 108 µg·min/mL |
| What carries the butyrate | L-lysine, an amino acid | Sodium, a mineral | Glycerol, a triglyceride backbone |
Single-dose ingredient study in 10 healthy men, using equal amounts of butyric acid. Results varied widely. Differences from sodium butyrate were not statistically significant.
A Pharmacokinetic Comparison of Three Butyrate Products
10 healthy men; randomized crossover; lysine butyrate, sodium butyrate and tributyrin, each providing 786 mg butyric acid.
Lysine and sodium butyrate produced greater systemic exposure and earlier peak concentrations than tributyrin. The mean lysine-butyrate peak occurred at the first post-dose sample, 20 minutes.
Read the original publicationButyrate and GLP-1
GLP-1 is a hormone your gut releases after meals that helps tell your brain you’re full. In mouse and cell studies, butyrate stimulated the L-cells that release GLP-1 and PYY, through a short-chain fatty acid receptor called FFAR2.
Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2.
Primary intestinal cell cultures and mice lacking the SCFA receptors FFAR2 or FFAR3.
Short-chain fatty acids stimulated GLP-1 release, and receptor disruption reduced this response. The findings support a receptor-mediated link between intestinal fermentation products and hormone secretion.
Read the original publicationBeneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion.
Mouse probiotic experiments plus cultured intestinal L cells exposed to butyrate.
The probiotic intervention was associated with greater butyrate and GLP-1, and butyrate directly stimulated GLP-1 release in the cell experiments. This supports a plausible microbiota–metabolite–hormone pathway.
Read the original publicationEffect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial.
60 adults with type 2 diabetes; four groups; sodium butyrate, inulin, both or placebo for 45 days.
Sodium butyrate alone and the butyrate–inulin combination increased GLP-1 compared with placebo. Several other changes were confined to combination treatment or comparisons within a group.
Read the original publicationThe full label
Other ingredients: Vegetable Capsule (Hypromellose), Silicon Dioxide, Dicalcium Phosphate, Microcrystalline Cellulose.
Allergen statement: This product is manufactured in a facility that also processes other products which may contain milk, eggs, fish, shellfish, tree nuts, peanuts, soy, wheat, and sesame.
Directions
As a dietary supplement, take 4 capsules once daily with water. 112 capsules ÷ 4 per day = 28 daily servings.
Ask your healthcare professional before use if you take medication, have a medical condition, are pregnant, or are breastfeeding.
1,000 mg BIOMEnd® per serving. No sodium carrier, no added oils.
Shop BIOMEnd® Butyrate†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. BIOMEnd® is a registered trademark of Velocity Life Sciences LLC.